[{"id":"ea39bf9b-3a98-46eb-8bfc-59230c1a4e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05395780","created_at":"2022-05-27T11:56:31.465Z","updated_at":"2024-07-02T16:36:09.466Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05395780","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-06-02"},{"id":"c7c7b388-a345-4c9d-9046-42dc16d8c6a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05369286","created_at":"2022-05-11T16:55:50.518Z","updated_at":"2024-07-02T16:36:10.590Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05369286","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2022-05-11"},{"id":"7911579f-d9ce-4a7c-80e3-eecd3f5c1c20","acronym":"","url":"https://clinicaltrials.gov/study/NCT01868022","created_at":"2021-01-18T08:21:31.110Z","updated_at":"2024-07-02T16:36:56.798Z","phase":"Phase 1","brief_title":"Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling","source_id_and_acronym":"NCT01868022","lead_sponsor":"GlaxoSmithKline","biomarkers":" FGF2","pipe":" | ","alterations":" FGFR1 amplification • FGFR1 expression","tags":["FGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification • FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • FP-1039"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 10/09/2013","start_date":" 10/09/2013","primary_txt":" Primary completion: 10/24/2017","primary_completion_date":" 10/24/2017","study_txt":" Completion: 10/24/2017","study_completion_date":" 10/24/2017","last_update_posted":"2019-08-19"},{"id":"819807a7-627e-40e5-a967-fc5eec1c4f69","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT02824133","created_at":"2021-01-18T13:50:52.751Z","updated_at":"2024-07-02T16:36:59.263Z","phase":"Phase 1/2","brief_title":"Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion\"","source_id_and_acronym":"NCT02824133 - TARGET","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" FGFR • TACC3 • TACC1","pipe":" | ","alterations":" FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion","tags":["FGFR • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fexagratinib (ABSK091)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2019-05-29"}]